Abstract
The recent advances in surgery and radiation therapy have significantly improved the prognosis of patients with primary cancer, and the major challenge of cancer treatment now is metastatic disease development. The 5-year survival rate of cancer patients who have distant metastasis at diagnosis is extremely low, suggesting that prediction and early detection of metastasis would definitely improve their prognosis because suitable patient therapeutic management and treatment strategy can be provided. Cancer cells from a primary site give rise to a metastatic tumor via a number of steps which require the involvement and altered expression of many regulators. These regulators may serve as biomarkers for predicting metastasis. Over the past few years, numerous regulators have been found correlating with metastasis. In this review, we summarize the findings of a number of potential biomarkers that are involved in cadherin–catenin interaction, integrin signaling, PI3K/Akt/mTOR signaling and cancer stem cell identification in gastrointestinal cancers. We will also discuss how certain biomarkers are associated with the tumor microenvironment that favors cancer metastasis.
Similar content being viewed by others
References
Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904
Yang SY et al (2011) Growth factors and their receptors in cancer metastases. Front Biosci 16:531–538
Locker GY et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327
Ishihara S et al (2010) Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer. Int J Colorectal Dis 25(12):1417–1425
Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104(1):66–73
Begent RH (1984) The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 21(Pt 4):231–238
Thomas P et al (1990) The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1032(2–3):177–189
Sorbye H, Dahl O (2003) Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 21(23):4466–4467
Sorbye H, Dahl O (2004) Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 43(5):495–498
Sato H et al (2010) Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol 40(11):1073–1080
Kim DH et al (2011) The relationships between perioperative CEA, CA 19–9, and CA 72–4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 104(6):585–591
Yakabe T et al (2010) Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 17(9):2349–2356
Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15(Suppl 4):14–22
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236
Di Bisceglie AM (2004) Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S104–S107
Daniele B et al (2004) Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S108–S112
Ucar E et al (2008) Prognostic value of preoperative CEA, CA 19–9, CA 72–4, and AFP levels in gastric cancer. Adv Ther 25(10):1075–1084
Nakajima K et al (1998) Impact of preoperative serum carcinoembryonic antigen, CA 19–9 and alpha fetoprotein levels in gastric cancer patients. Tumour Biol 19(6):464–469
Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3(1):55–63
Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26
Zhang CH et al (2010) Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res 174(1):120–129
Boo YJ et al (2007) L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14(5):1703–1711
Saad AA et al (2010) Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. Ann Surg Oncol 17(11):3059–3067
Uchikado Y et al (2011) Increased slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer 14(1):41–49
Castro Alves C et al (2007) Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol 211(5):507–515
Joo YE et al (2002) Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2(2):129–137
Zhao XJ et al (2003) Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol 9(2):225–232
Chan AO et al (2005) Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 104(4):740–746
Chan AO et al (2001) Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 48(6):808–811
Soyama A et al (2008) Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 55(85):1390–1393
Okugawa Y et al (2011) Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res 175(2):e67–e73
Chung Y et al (2011) Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 24(1):49–55
Weiss JV et al (2011) Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 128(6):1384–1392
Pedrazzani C et al (2008) Influence of age on soluble E-cadherin serum levels prevents its utility as a disease marker in gastric cancer patients. Scand J Gastroenterol 43(6):765–766
Batlle E et al (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2(2):84–89
Cano A et al (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2(2):76–83
Zhang K et al (2011) Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest 91(3):426–438
Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142
Min AL et al (2009) High expression of snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin Exp Metastasis 26(7):759–767
Otsuki S et al (2011) Vimentin expression is associated with decreased survival in gastric cancer. Oncol Rep 25(5):1235–1242
Hu L et al (2004) Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23(1):298–302
Gal A et al (2008) Sustained TGF beta exposure suppresses smad and non-smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27(9):1218–1230
Kaplan RN et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827
Iwatsuki M et al (2010) The clinical significance of vimentin-expressing gastric cancer cells in bone marrow. Ann Surg Oncol 17(9):2526–2533
Shirahata A et al (2010) Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. Anticancer Res 30(12):5015–5018
Sugimachi K et al (2003) Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin Cancer Res 9(7):2657–2664
Miyoshi A et al (2005) Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br J Cancer 92(2):252–258
Yin T et al (2007) Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res 141(2):196–203
Natsugoe S et al (2007) Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep 17(3):517–523
Shioiri M et al (2006) Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 94(12):1816–1822
Uchikado Y et al (2005) Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 11(3):1174–1180
Yang MH et al (2009) Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 50(5):1464–1474
Zhao XL et al (2011) Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med 15(3):691–700
Lee TK et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12(18):5369–5376
Niu RF et al (2007) Up-regulation of twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 26(3):385–394
Gomez I et al (2011) TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS ONE 6(3):e18023
Ru GQ et al (2011) Upregulation of twist in gastric carcinoma associated with tumor invasion and poor prognosis. Pathol Oncol Res 17(2):341–347
Yan-Qi Z et al (2007) Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology 39(5):470–475
Ohk Sung C et al (2011) Twist1 is up-regulated in gastric cancer-associated fibroblasts with poor clinical outcomes. Am J Pathol 179(4):1827–1838
Gong T et al (2012) Nuclear expression of twist promotes lymphatic metastasis in esophageal squamous cell carcinoma. Cancer Biol Ther 13(8):606–613
Forghanifard MM et al (2012) Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol 19(3):743–749
Xie F, Li K, Ouyang X (2009) Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis 26(8):1025–1032
Yuen HF et al (2007) Upregulation of twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60(5):510–514
Ohuchida K et al (2007) Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of twist expression in pancreatic juice. Int J Cancer 120(8):1634–1640
Sun T et al (2010) Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51(2):545–556
Che N et al (2011) The role of Twist1 in hepatocellular carcinoma angiogenesis: a clinical study. Hum Pathol 42(6):840–847
Sun T et al (2011) Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 54(5):1690–1706
Zhou YM et al (2011) Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol 19(5):1700–1706
Zhu W et al (2011) Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 61(4):562–575
Tang DJ et al (2010) Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 51(4):1255–1263
Lee NP et al (2010) Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 127(4):968–976
Meng HM et al (2010) Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 9(4):295–302
Fu J et al (2011) p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 53(1):181–192
Zheng P et al (2011) Snail as a key regulator of PRL-3 gene in colorectal cancer. Cancer Biol Ther 12(8):742–749
Kim NW et al (2011) Correlation between liver metastases and the level of PRL-3 mRNA expression in patients with primary colorectal cancer. J Korean Soc Coloproctol 27(5):231–236
Bardelli A et al (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9(15):5607–5615
Kato H et al (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10(21):7318–7328
Mollevi DG et al (2008) PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer 99(10):1718–1725
Peng L et al (2004) The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 130(9):521–526
Guzinska-Ustymowicz K et al (2011) Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer. Adv Med Sci 56(1):39–43
Miskad UA et al (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71(4):176–184
Ooki A et al (2009) Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep 21(6):1467–1475
Wang Z et al (2008) Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int J Cancer 123(6):1439–1447
Miskad UA et al (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450(3):303–310
Pryczynicz A et al (2010) PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer. Folia Histochem Cytobiol 48(4):632–636
Zhao WB et al (2008) Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma. Int J Mol Med 22(2):187–192
Mayinuer A et al (2012) Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma. Ann Surg Oncol 20(1):305–317
Liu YQ et al (2008) Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma. Arch Pathol Lab Med 132(8):1307–1312
Ooki A et al (2010) Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer 127(3):543–554
Zheng P et al (2010) Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 9(10):4897–4905
Hsieh SY et al (2010) Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49(5):476–487
Wang H et al (2010) PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 18(1):52–62
Zhang T et al (2010) PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells. Mol Cancer 9:72
Wong SC et al (2004) Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res 10(5):1613–1617
Zekri AR et al (2011) Serum levels of beta-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol Rep 26(4):825–831
Gavert N et al (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168(4):633–642
Zander H et al (2011) Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients. BMC Cancer 11(189):1–7
Brabletz T, Jung A, Kirchner T (2002) Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 441(1):1–11
Liu L et al (2010) Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16(10):2740–2750
Matsukuma S, Sato K (2011) Peritoneal seeding of hepatocellular carcinoma: clinicopathological characteristics of 17 autopsy cases. Pathol Int 61(6):356–362
Cheng XX et al (2005) Correlation of Wnt-2 expression and beta-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett 223(2):339–347
Choi MG et al (2010) Mucinous gastric cancer presents with more advanced tumor stage and weaker beta-catenin expression than nonmucinous cancer. Ann Surg Oncol 17(11):3053–3058
Takayama T et al (1998) Aberrant expression and phosphorylation of beta-catenin in human colorectal cancer. Br J Cancer 77(4):605–613
Miyamoto S et al (2004) Nuclear beta-catenin accumulation as a prognostic factor in Dukes’ D human colorectal cancers. Oncol Rep 12(2):245–251
Chen WC et al (2007) Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray. World J Gastroenterol 13(5):699–708
Zhang B et al (2003) Beta-catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 9(8):3073–3079
Hervieu V et al (2006) Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases. J Clin Pathol 59(12):1300–1304
Wang W, Xue L, Wang P (2011) Prognostic value of beta-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. Med Oncol 28(1):163–169
Ben QW et al (2010) Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 17(8):2213–2221
Tsutsumi S et al (2011) L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J Surg Oncol 103(7):669–673
Kim MY, Han SI, Lim SC (2011) Roles of cyclin-dependent kinase 8 and beta-catenin in the oncogenesis and progression of gastric adenocarcinoma. Int J Oncol 38(5):1375–1383
Yang P et al (2009) Enhanced activity of very low density lipoprotein receptor II promotes SGC7901 cell proliferation and migration. Life Sci 84(13–14):402–408
He L et al (2010) Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to beta-catenin in different cancers. BMC Cancer 10:601
Kim B et al (2006) TC1(C8orf4) correlates with Wnt/beta-catenin target genes and aggressive biological behavior in gastric cancer. Clin Cancer Res 12(11 Pt 1):3541–3548
Boissan M et al (2010) Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res 70(19):7710–7722
Zhang S et al (2011) EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene 30(50):4941–4952
Yamaguchi A et al (1994) Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular cacinoma. Cancer 73(9):2280–2284
Kodera Y et al (1994) Expression of nm23 H-1 RNA levels in human gastric cancer tissues. A negative correlation with nodal metastasis. Cancer 73(2):259–265
Liu WK et al (2009) The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma. Onkologie 32(10):574–578
Liu WK et al (2005) The relationship between HPV16 and expression of CD44v6, nm23H1 in esophageal squamous cell carcinoma. Arch Virol 150(5):991–1001
Elagoz S et al (2006) The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. Pathol Oncol Res 12(1):21–27
Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20(3):203–213
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22
Ke JJ, Shao QS, Ling ZQ (2006) Expression of E-selectin, integrin beta1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J Gastroenterol 12(22):3609–3611
Zhao ZS et al (2011) Expression and prognostic significance of CEACAM6, ITGB1, and CYR61 in peripheral blood of patients with gastric cancer. J Surg Oncol 104(5):525–529
Kuo ML et al (2005) Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappa B/cyclooxygenase-2 signaling pathway. Clin Cancer Res 11(16):5809–5820
Li H et al (2011) HIF-1alpha-activated ANGPTL4 contributes to tumor metastasis via VCAM-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology 54(3):910–919
Zhou G et al (2012) Detection and clinical significance of CD44v6 and integrin-beta1 in pancreatic cancer patients using a triplex real-time RT-PCR assay. Appl Biochem Biotechnol 167(8):2257–2268
Zhou G et al (2012) The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-beta1, CA199, and CEA. Mol Biotechnol 52(1):59–67
Lu JG et al (2011) Overexpression of osteopontin and integrin alphav in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol 137(11):1613–1618
Wu CY et al (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56(6):782–789
Sun J et al (2010) The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 136(1):1–7
Zhang H et al (2006) The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132(11):709–717
Shimada Y et al (2005) Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68(2–3):285–292
Wild N et al (2010) A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 16(24):6111–6121
Fransvea E et al (2009) Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49(3):839–850
Zhao ZS et al (2010) SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 16(1):260–268
Ura H et al (1998) Separate functions of alpha2beta1 and alpha3beta1 integrins in the metastatic process of human gastric carcinoma. Surg Today 28(10):1001–1006
Giannelli G et al (2002) Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161(1):183–193
Hosotani R et al (2002) Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 25(2):e30–e35
Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 14(1):74–81
Pan HW et al (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98(1):119–127
Ye QH et al (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9(4):416–423
Higashiyama M et al (2007) Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14(12):3419–3427
Takafuji V et al (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26(44):6361–6371
Collins AL et al (2012) Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 19(8):2673–2678
Huang X et al (2009) Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep 21(4):1123–1129
Zeng ZJ et al (2004) Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance. World J Gastroenterol 10(23):3414–3418
Weaver MS, Workman G, Sage EH (2008) The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 283(33):22826–22837
Wang CS et al (2004) Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 91(11):1924–1930
Che Y et al (2006) The differential expression of SPARC in esophageal squamous cell carcinoma. Int J Mol Med 17(6):1027–1033
Nakayama T et al (2011) Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep 25(4):929–935
Makrilia N et al (2009) Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 27(10):1023–1037
Hannigan GE et al (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379(6560):91–96
Bravou V et al (2006) ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol 208(1):91–99
Ito R et al (2003) Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch 442(2):118–123
Chan J et al (2011) Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS ONE 6(2):e16984
Wang WS et al (2004) Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23(39):6666–6671
Huang HC et al (2007) Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26(19):2781–2790
Tang MC et al (2011) Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. Cancer Lett 308(2):162–171
Albasri A et al (2011) Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene 30(26):2997–3002
Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14(1):77–94
Chen JS et al (2010) FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 27(2):71–82
Park JH et al (2010) Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol 41(12):1664–1673
Su JM et al (2002) Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 8(4):613–618
Miyazaki T et al (2003) FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 89(1):140–145
Chatzizacharias NA et al (2010) Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas 39(6):930–936
Furuyama K et al (2006) Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 30(2):219–226
Liu AW et al (2011) ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 17(4):710–720
Hao JM et al (2010) A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol 220(4):475–489
Liang JJ et al (2008) Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 14(21):7043–7049
Itoh S et al (2007) Role of growth factor receptor bound protein 7 in hepatocellular carcinoma. Mol Cancer Res 5(7):667–673
Tanaka S et al (2006) Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 98(7):491–498
Peng L et al (2009) Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 30(10):1660–1669
Wu F et al (2009) Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 50(6):1839–1850
Wu F et al (2011) Down-regulation of EGFL8: a novel prognostic biomarker for patients with colorectal cancer. Anticancer Res 31(6):2249–2254
Parker LH et al (2004) The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 428(6984):754–758
Fitch MJ et al (2004) Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn 230(2):316–324
Huang J et al (2010) Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 120(1):223–241
Chen M et al (2010) Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387–1391
Jiang BH, Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784(1):150–158
Jiang BH, Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19–65
Bi J et al (2009) Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 40(12):1790–1797
Zhu CB et al (2012) Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol 19(3):817–825
Zhang XW et al (2010) BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 9:40
Yoshioka A et al (2008) The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep 19(5):1099–1107
Yu G et al (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 15(5):1821–1829
Kasajima A et al (2011) mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18(1):181–192
An JY et al (2010) Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126(12):2904–2913
Zhang YJ et al (2009) mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 16(9):2617–2628
Liao WT et al (2011) HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 17(11):3569–3578
Nguyen Kovochich A et al (2012) HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer 119(3):529–539
Song W et al (2010) Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101(7):1754–1760
Liu WL et al (2010) Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer 10:467
Wang H et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(5):535–541
Sasaki M et al (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88(8):873–882
Pang R et al (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6(6):603–615
Iinuma H et al (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol 29(12):1547–1555
Lin EH et al (2007) Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110(3):534–542
Mehra N et al (2006) Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12(16):4859–4866
Yu JW et al (2010) Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res 29:141
Hou Y et al (2011) The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res 22(1):259–272
Kure S et al (2012) Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Int J Oncol 41(4):1314–1324
Maeda S et al (2008) CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 98(8):1389–1397
Yang XR et al (2009) CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 15(17):5518–5527
Darwish NS et al (2004) Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 36(5):298–302
Lee TK et al (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9(1):50–63
Ikenaga N et al (2010) Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum Pathol 41(10):1466–1474
Chen T et al (2011) Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 22(1):248–258
Han ME et al (2011) Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 68(21):3589–3605
Yokoyama S, Yamaue H (2002) Prediction of distant metastasis by using reverse transcriptase-polymerase chain reaction for epithelial and variant CD44 mRNA in the peripheral blood of patients with colorectal cancer. Arch Surg 137(9):1069–1073
Bunger S et al (2012) Pancreatic carcinoma cell lines reflect frequency and variability of cancer stem cell markers in clinical tissue. Eur Surg Res 49(2):88–98
Wang Y et al (2012) Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China. Dis Esophagus 25(6):560–565
Minato T et al (2012) Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 20(1):209–217
Wakamatsu Y et al (2012) Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 62(2):112–119
Chen XQ, He JR, Wang HY (2012) Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma. Med Oncol 29(3):1843–1849
Hessman CJ et al (2012) Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. Am J Surg 203(5):649–653
Kahlert C et al (2011) Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer 11:275
Yang XR et al (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59(7):953–962
Lorusso G, Ruegg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130(6):1091–1103
Liang JF et al (2010) Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 29:71
Yoshimura T et al (2011) Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment. Epigenetics 6(8):1001–1011
Infante JR et al (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25(3):319–325
Imano M et al (2011) Osteopontin induced by macrophages contribute to metachronous liver metastases in colorectal cancer. Am Surg 77(11):1515–1520
Wang JM et al (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54(3):363–370
Bellone G et al (2007) Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence. Ann Surg Oncol 14(11):3232–3242
Ding S et al (2006) Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 37(7):861–866
Yang LY et al (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6:110
Ho JW et al (2005) Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 11(2):176–181
Romani AA et al (2006) The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 93(6):446–455
Saad RS et al (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17(2):197–203
Koyama Y et al (2010) Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer. Exp Ther Med 1(4):627–633
Budhu A et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10(2):99–111
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ng, L., Poon, R.T.P. & Pang, R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell. Mol. Life Sci. 70, 3631–3656 (2013). https://doi.org/10.1007/s00018-013-1266-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-013-1266-8